PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange has achieved yet another goal by completion of enrollment of 80 patients in its phase II Dry Eye Syndrome trial. Approximately 80 patients were enrolled to this study, randomized into 2 groups treated with 1 mg of CF101 and placebo. Patients are taking the drug for 12 weeks plus 2 weeks of follow-up. The trial is being conducted in 6 sites in Israel. The company expects to release study data on Q2 2009.
